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 Introduction 
 Alzheimer’s disease (AD) is a progressive neurodegen-
erative condition. In Germany, there are an estimated 
900,000 patients with dementia, of whom 650,000 suffer 
from AD  [1] . Every year, 200,000 new cases of dementia 
are diagnosed, including approximately 120,000 cases of 
AD  [1] . Age is still considered to be the greatest risk fac-
tor for dementia, so, with the proportion of elderly people 
increasing in the population, it is anticipated that the 
number of cases of dementia will continue to rise  [1] . 
 Alongside the cholinergic deficit seen in AD  [2] , dis-
turbances in the glutamate system also occur  [3] . Gluta-
mate is the most important excitatory neurotransmitter 
because approximately 70% of all excitatory CNS syn-
apses are glutamatergic  [3] . Although not all of the pro-
cesses involved in the pathogenetic mechanism are 
known, there are numerous specific findings regarding 
the emergence of impaired neurotransmission and neu-
ronal cell death, as well as the role of glutamate. In AD, 
there is a rise in the concentration of glutamate in the 
synaptic cleft, either through increased release into the 
cleft or through reduced reabsorption out of the cleft  [4] . 
This increase in glutamate not only leads to disruption of 
signal transduction but also causes excitotoxic effects 
 [4, 5] . 
 There are currently 2 approved therapeutic options for 
the treatment of AD: cholinesterase inhibitors (ChEIs), 
which counteract the cholinergic deficit  [6, 7] , and me-
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mantine, an uncompetitive N-methyl- D -aspartate recep-
tor antagonist that improves neuronal signal transduc-
tion and demonstrates neuroprotective properties  [4, 8] . 
While ChEIs are approved for the treatment of mild to 
moderate AD, memantine has been a therapy option for 
the advanced stages of AD since 2002. In controlled clin-
ical studies among patients with moderate to severe AD, 
memantine has demonstrated efficacy and tolerability 
both as a monotherapy and in combination therapy with 
a ChEI  [9–11] . The efficacy of memantine was also shown 
for milder forms of AD  [12] . In these placebo-controlled, 
double-blind studies, memantine was significantly supe-
rior to placebo in the areas of cognition, ability to per-
form activities of daily living and overall clinical impres-
sion. 
 Due to strict inclusion and exclusion criteria, only very 
select patient populations are examined in clinical stud-
ies, and therefore the aim of the observational study de-
scribed here was to examine the efficacy and tolerability 
of memantine under naturalistic conditions, i.e. in a het-
erogeneous patient population in daily practice. In order 
to meet with the quality assurance requirements imposed 
on observational studies, a multidimensional question-
naire with options for self-evaluation and external evalu-
ation by the caregiver was used.  
 Methods 
 In an open - label, multi-centre post-marketing observational 
study, patients with AD were treated with 20 mg/day of meman-
tine for 6 months. The physicians who participated were primar-
ily in private practice (general medicine practitioners, neurolo-
gists and psychiatrists). 
 Patient Population 
 A total of 2,000 patients with moderate to severe AD (based 
on ICD-10 criteria) were accepted into the observational study. 
No specific requirements were in place for the selection of pa-
tients, apart from an attending physician’s positive diagnosis of 
dementia made in accordance with clinical criteria. The excep-
tion was that the patients were not allowed to participate in a clin-
ical trial at the same time because therapy with memantine could 
have been incompatible with the trial medication. Also, the con-
traindications and safety measures listed in the memantine pre-
scribing information had to be observed. 
 Outcome Measures 
 At the beginning of the study, demographic data and informa-
tion on any previous therapy with antidementia drugs, and any 
concomitant diseases and medications, was collected. The pa-
tients were examined at 3 points during the study – during an 
initial examination and subsequently at efficacy evaluations after 
3 and 6 months. At each examination, the Mini-Mental State Ex-
amination (MMSE)  [13] and the Nurses’ Observation Scale for 
Geriatric Patients (NOSGER)  [14] were used to test cognitive per-
formance and to externally evaluate the patients’ ability to per-
form activities of daily living, respectively. Alongside these as-
sessments, the Explorationsmodul Demenz (EMD) (Dementia 
Exploration Module) was used in the initial and 6-month exami-
nations (manuscript in preparation). The EMD is a psychometric 
questionnaire that uses 13 simple closed questions on the areas of 
cognition (area A), everyday behaviour and affectivity (area B), 
and disease-related self-awareness (area C). The responses are 
used to generate a self-evaluation, as well as a collateral evaluation 
of the patient’s condition, with respect to the negative effects of 
dementia on activities of daily living and to the subjective percep-
tion of such effects. This process makes an evaluation of memory 
and other cognitive disruptions possible, as well as an assessment 
of independence, communication, mood and motivation. This di-
mension-specific evaluation is performed by the patient and by 
the caregiver. 
 The overall clinical impression was evaluated by the treating 
physician according to a 3-step scale (improved, stabilised, dete-
riorated). The effect of memantine on cognitive abilities and the 
ability to perform activities of daily living was assessed using a 
4-step scale (very good, good, fair and poor). Tolerability was 
evaluated by the physician in the same way. At each examination 
point, the patients were asked whether they had experienced any 
adverse events (AEs), and these were documented according to 
international standards of good clinical practice. The dosage of 
memantine was recorded after 3 and 6 months. In the case of pre-
mature termination of the therapy, the reasons for cessation were 
ascertained. 
 Statistical Analysis 
 Statistical analysis of the effects of treatment was performed 
using parametric tests. Individual missing values were not taken 
into account when analysing the data collected after the 3- and 
6-month time points – ‘observed case’ population. With respect 
to safety and tolerability, the analysis was descriptive. 
 Results 
 Patient Characteristics 
 A total of 1,845 patients were included in this observa-
tional study. It was possible to evaluate efficacy data from 
1,580 patients, with 265 being excluded for various rea-
sons ( 1 1 answer was possible): for 72 patients, no treat-
ment documentation was available, for 60 there was no 
evaluation after 3 or 6 months, a further 73 had MMSE 
scores of  1 27, and for 130 patients, retrospective docu-
mentation was the reason for exclusion. 
 Newly diagnosed cases were included in the study 
alongside patients with existing AD diagnoses ( table 1 ). 
The mean age of the patients included in the study was 
76.3  8 8.7 years, and 58.2% were female ( table 1 ). A total 
of 60.9% of the patients had received prior treatment for 
AD, and of these (taking into consideration multiple an-
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swers), 24.9% had received ginkgo extracts, 20.1% pirace-
tam, and 17.3% had taken ChEIs. Additionally, during 
the study, 21.6% of the patients also received another an-
tidementia drug. Along with AD, 74.4% suffered from at 
least 1 additional concomitant disease, the most common 
of these being cardiovascular disease ( table 1 ). Corre-
spondingly, comedication was indicated for 65.4% of the 
patients, with 41.2% receiving antihypertensive drugs. In 
addition, cases of comedication included the use of anti-
diabetic drugs (13.4%), antidepressants (11.3%) and neu-
roleptic drugs (9.3%). 
 At the initial examination, the mean MMSE score was 
15.4  8 5.7. The mean doses of memantine received were 
17.1  8 5.8 and 17.3  8 5.8 mg after 3 and 6 months, re-
spectively. In total, 185 patients (10.1%) terminated me-
mantine therapy before completion of the 6-month ob-
servation. The reasons indicated were patient’s wishes 
(3.4%), lack of efficacy (3.3%), AEs (3.1%) or other rea-
sons (2.4%) (multiple answers possible). 
 Efficacy 
 Memantine led to an improvement in symptoms as 
determined by all the examination measures in this study 
(cognition, activities of daily life and physician’s global 
assessment). After 6 months of therapy, the MMSE had 
improved by 2.5  8 4.5 points (n = 1,199; p  ! 0.0001; 
 fig. 1 ), and in the responder analysis, the MMSE score 
increased by at least 1 point in 68.2% of the patients 
( fig. 2 ). An improvement of 1–2 points was seen in 17.0% 
of the patients, a further 34.4% improved by 3–6 points, 
and the scores for 16.8% of the patients increased by  1 6 
points. Stabilisation of core cognitive symptoms was 
shown in 9.6% of the patients ( fig. 2 ). 
 With the NOSGER, a significant improvement over 
the initial values in all 6 dimensions was observed after 3 
and 6 months ( fig. 3 ). 
 Changes to the individual dimensions of the EMD 
over the study period were calculated as the change from 
baseline in the median number of overall points in each 
dimension ( fig. 4 ). This showed a significant (p  ! 0.0001) 
decrease (improvement) in the patient and external (care-
 Table 1. Patient characteristics 
Sex, % female 58.2
Mean age 8 SD, years 76.388.7
Mean height 8 SD, cm 167.188.1
Mean weight 8 SD, kg 70.3811.5
Mean duration of AD 8 SD, years 2.481.9
Concomitant diseases (% patients)
Hypertension 44.5
Heart failure 24.0
Arteriosclerosis 19.7
Other cardiac diseases 2.6
Diabetes mellitus 17.2
Other 22.4
Mean MMSE score at baseline 8 SD (n = 1,496) 15.485.7
Concomitant diseases: multiple answers possible.
Baseline
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 Fig. 1. Mean MMSE scores at baseline and after 3 and 6 months 
of treatment with memantine (observed case analysis).  * p  ! 
0.0001 vs. baseline; t test. 
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 Fig. 2. Responder analysis – patients (percent) with stabilisation 
or improvement (1 to  6 6 points) in MMSE score after 6 months 
of treatment with memantine (vs. baseline). 
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giver) assessments of daily performance with respect to 
the EMD total score. The clearest improvement was seen 
in the ‘social behaviour’ dimension for both the self-as-
sessment and the external (caregiver) assessment. 
 Moreover, for the MMSE as well as the NOSGER, 
 effect sizes for individual items of each scale were calcu-
lated. In this process, the difference between the baseline 
data and the result of the interim measurement after 
3 months (interval effect, for NOSGER and MMSE) or at 
the end of the observation period after 6 months (pri-
mary effect, for NOSGER and MMSE) was compared. 
For the NOSGER, the largest effect sizes were shown in 
the ‘mood’ and ‘disturbing behaviour’ dimensions, and 
in the MMSE it was the items ‘orientation’ and ‘recall’, in 
particular, that contributed to the primary effect. 
 In the overall evaluation by the treating physician, sta-
bilisation of, or improvement in, symptoms had been 
achieved in 78.8% of the patients after 6 months of ther-
apy ( fig. 5 ). In evaluating cognitive performance after 6 
months of treatment with memantine, a very good or 
good effect was indicated for 37.6% of the patients, a mod-
erate effect for 40.9%, and for 16.2% of the patients, cog-
nitive performance was evaluated as being poor ( fig. 6 ). 
A similar pattern was seen in the evaluation of efficacy 
with respect to activities of daily living. For 47.7% of the 
patients, this was indicated as being very good to good, 
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–1.1 –1.1
–1.5
–0.6
–0.8
–0.7
–1.3
–1.2
–0.6
–0.9
–0.3
0
–0.2
–0.4
–0.6
–0.8
–1.2
–1.4
–1.6
–1
Memory
3 months
6 months
Im
p
ro
ve
m
en
t
M
ea
n
 c
h
an
g
e 
fr
om
 b
as
el
in
e
in
 N
O
SG
ER
 s
co
re
s
ADLIADL
NOSGER scale items
Mood Disruptive
behaviour
Social
behaviour
 Fig. 3. Improvement in NOSGER items af-
ter 3 and 6 months of treatment with me-
mantine (vs. baseline). p  ! 0.0001 vs. base-
line at 3 and 6 months, for all items. p  ^  
0.0001 3 months vs. 6 months. IADL = 
 Instrumental activities of daily living; 
ADL = activities of daily living. 
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 Fig. 4. Mean EMD scores for each area at 
baseline and after 6 months of treatment 
with memantine.  * p  ! 0.0001. A = Cogni-
tion; B = everyday behaviour and affectiv-
ity; C = disease-related self-awareness. 
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in 32.7% it was moderate, and for 12.6% of the patients, 
efficacy was deemed to be poor ( fig. 6 ). 
 Safety and Tolerability 
 A total of 87 (4.7%) out of 1,845 patients experienced 
at least 1 AE during the study, with 224 AEs documented 
in all. Of these AEs, 58% appeared to have no connection 
with the memantine treatment, and no particular trends 
in AEs were observed, with a wide variety of different 
events reported. The most frequently reported AEs were 
either psychiatric (1.8%) or neurological (1.7%), with all 
other organ systems being affected in  ! 1% of the patients. 
The most common AEs ( 6 0.2%) are listed in  table 2 . Of 
these, 2.7% were classified as severe AEs, the majority of 
which led to hospitalisation because of either a deteriora-
tion in the patient’s overall state or an existing concomi-
tant disease. For 87.8% of the patients with severe AEs, no 
connection with the therapy was seen. 
 In total, 24 out of 1,845 patients (1.3%) died during the 
observation study. The most frequent causes were car-
diovascular diseases, apoplexy, pneumonia and deterio-
ration in the overall state of the patient or senile atrophy. 
In 23 of these patients, anamnestic cardiovascular dis-
eases, diabetes mellitus, arteriosclerosis and/or condi-
tions following apoplexy were documented, however, 
memantine was not believed to be the cause in any of 
these  cases. 
 The good level of tolerability of memantine was also 
reflected in the physicians’ global evaluation, where tol-
erability was classed as very good in 63% of the patients 
and good in a further 30%. 
 Discussion 
 In the post-marketing observational study described 
here, the efficacy and tolerability of memantine were 
demonstrated in a heterogeneous patient population. 
 Whilst the clinical testing of medications is typically 
carried out on a relatively small number of patients who 
have been selectively chosen for clinical examination, the 
results of observational studies tend to provide a more 
accurate reflection of daily practice. In these observa-
tional studies, inclusion and exclusion criteria are usu-
ally broadly structured and because of this, these studies 
42.3
36.5
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Improvement Stabilisation Deterioration No answer
 Fig. 5. Physician’s overall clinical evaluation after 6 months of 
treatment with memantine. 
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 Fig. 6. Physician’s global evaluation of cognition and daily func-
tioning after 6 months of treatment with memantine. 
 Table 2. Patients with adverse events (inci-
dence ≥0.2%) 
Adverse event Patients, %
Restlessness 0.5
Dizziness 0.4
Pneumonia 0.4
Deterioration of AD 0.4
Confusion 0.3
Cerebrovascular events 0.3
Heart failure 0.3
Aggression 0.3
Dehydration 0.3
Nausea 0.2
Paranoia 0.2
Agitation 0.2
Urinary tract infection 0.2
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tend to have more naturalistic conditions when com-
pared to clinical examinations. For this reason, any rare 
or very rare adverse effects, interactions or other dangers 
in connection with the use of the medication can be 
recognised more frequently in observational studies. 
Knowledge of the efficacy, safety and interactions of a 
medicine tends to be incomplete when it is first approved. 
New findings regarding the safety of medications can 
arise long after the approval of the drug, and sometimes 
the particular interactions of well-known substances are 
only discovered at a later date, following new develop-
ments in medical science. Consequently, it appeared to be 
sensible to conduct a broadly structured study of the ef-
ficacy and tolerability of memantine with a representa-
tive patient sample. Furthermore, the Arzneimittelgesetz 
(Pharmaceuticals Act) of the Federal Republic of Germa-
ny requires that additional, systematic gathering and 
analysis of information on pharmaceuticals should be 
carried out even after they have been approved for me-
dicinal use. 
 Over the course of 6 months of treatment with me-
mantine, it was possible to document any stabilisation or 
improvement of the patients’ AD using the MMSE. At the 
end of the 6-month observation, the MMSE score had 
improved significantly, with a responder analysis reveal-
ing that 68% of the patients had improved MMSE scores. 
In a meta-analysis based on cognitive decline in AD pa-
tients, Han et al.  [15] showed that MMSE scores declined 
in untreated patients by 3.3 points annually. By contrast, 
the average MMSE value in the examination discussed 
here rose by 2.5 points, indicating a clear improvement in 
cognitive symptoms. The results of the NOSGER also in-
dicated an improvement in memory, activities of daily 
living and behaviour. This effect was most evident in the 
areas of mood as well as in behavioural dimensions. In 
addition, after 6 months of treatment with memantine, 
this positive effect was even more pronounced for indi-
vidual items of these scales. With this therapeutic ap-
proach, it was thus possible to obtain an effect compara-
ble to that documented under cholinergic therapy with 
donepezil  [16] . 
 The average EMD scores showed a statistically signif-
icant decrease after the 6-month observation in both self-
evaluation and caregiver-referenced evaluation. Interest-
ingly, the daily functions initially rated by the caregiver 
as being the most adversely affected were those that un-
derwent the most improvement in the caregiver evalua-
tion at the end of the observation period. This may be 
viewed as a relevant reduction in caregiver burden. 
 The clinical relevance of these findings is borne out by 
the global evaluations. The evaluation of the overall clin-
ical impression, as well as that of the efficacy of meman-
tine with respect to cognition and daily functions, showed 
that the effects measured using the MMSE, NOSGER and 
EMD were also visible to the treating physician. 
 In controlled clinical studies over 6 months, it was 
possible to show that under therapy with memantine, sta-
bilisation or improvement of symptoms occurred  [9, 11, 
12] . The observational study discussed here confirms 
that the effects demonstrated in clinical studies are rele-
vant to everyday practice. However, for patients with ad-
vanced dementia, objective tools may not be the best way 
to measure these effects on cognitive performance due to 
floor effects. On the other hand, self-assessment of pos-
sible deficits can, for the same reasons, also lead to distor-
tions. In fact, the EMD results under discussion show 
that subjective assessments by the patient and caregiver 
can differ substantially. Therefore, in the case of patients 
with advanced dementia, including those with reduced 
powers of judgement, it appears all the more important 
to include behaviour-related judgement items and, in 
particular, those relevant to activities of daily living and 
care, along with cognitive items. 
 With respect to the comorbidity of the patients and the 
necessary comedication, the tolerability of an antidemen-
tia therapy is especially important. In total, 74.4% of the 
patients included in this observational study suffered 
from at least 1 concomitant disease, with 60.7% citing 
cardiovascular diseases. Correspondingly, comedication 
was given to 65.4% of the patients. For 4.7%, at least 1 AE 
occurred, which, due to the general state of the patients’ 
health, is to be viewed as a low rate. None of the individ-
ual AEs occurred at a frequency  1 0.5%. Furthermore, the 
AEs that did occur corresponded to those reported in 
clinical studies, but with a lower incidence  [9, 10, 17] . Of 
the 1.3% of patients who died during the course of this 
6-month observation study, which corresponds to the 
frequency observed in other clinical studies  [9] , anam-
nestic cardiovascular diseases, diabetes mellitus, arterio-
sclerosis and/or apoplexy were present. This percentage 
is also in line with the number of deaths expected due to 
the age structure of the population studied and the ac-
companying high number of patients who additionally 
presented with at least 1 further disease  [18] . 
 The results of this observational study have shown 
that the effects of memantine, which have already been 
demonstrated in clinical studies, can also be achieved in 
everyday practice. The results of this study are compa-
rable with those of the observational study published by 
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Hager et al.  [16] , in which the efficacy of donepezil for AD 
was examined over a 3-month period. After 3 months of 
therapy, memantine demonstrates equally good efficacy. 
Memantine is, however, distinguished by its more fa-
vourable tolerability profile, which is maintained even 
beyond the conventional study period for observation 
studies and without any loss of efficacy. 
 Taken together, the results of the observation study 
presented here show that, because of its good efficacy and 
tolerability, memantine represents an appropriate thera-
py option for the treatment of the cognitive as well as the 
non-cognitive effects of moderate to severe AD. The pos-
itive results achieved by this intervention are shown us-
ing realistic investigative tools and can be observed in 
everyday treatment relevant to usual practice. 
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